New Standard Likely for Some Metastatic HER2 Breast Cancer

The investigational oral therapy tucatinib, when added to standard trastuzumab and capecitabine, resulted in a “clinically meaningful” lower risk of disease progression or death compared with placebo

Read the full article here

Related Articles